Scholar Rock Holding Corp. (SRRK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$45.50-1.28%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SRRK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -11.1% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 44.6% |
Growth built into the price is above our model estimate.
The price assumes 55.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
SRRK — earnings in line
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exc…
Why it matters: The study is the next human test of this new drug. Clear safety and dose data would support further testing.
Watch forThe late-2026 data show no safety issue that limits the dose. They support more dose testing.
Also watch forThe data show a safety issue that limits the dose, or the company delays results beyond late 2026.
Why it matters: The company is loss-making and reported $492.1 million in cash and investments at June 30. A sharp drop could raise funding concerns.
Worry ifA later report shows less than $492.1 million in cash, cash equivalents, and marketable securities. It shows no clear path to runway into 2027.
Less concerning ifA later report shows $492.1 million or more in cash and investments. Management still cites runway into 2027.
Why it matters: FORGE tests apitegromab in FSHD, a new disease area. A rise in lean muscle volume would support this use beyond SMA.
Supportive ifAt 12 months, FORGE reports a rise in mean lean muscle volume from baseline. The rise favors apitegromab over placebo.
Worry ifAt 12 months, mean lean muscle volume does not rise from baseline. Or it does not rise more with apitegromab than with placebo.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $440 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,404 loss on $10,000 · 34.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.